Journal: PLOS One
Article Title: Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves (Leverages) cisplatin treatment efficacy
doi: 10.1371/journal.pone.0336190
Figure Lengend Snippet: (A) Effect of bpDNase on GCT proliferation. (B) Pulmozyme® rhDNase does not inhibit proliferation of healthy human testicular fibroblasts or EC cells NT2. (C) DNase does not affect the chemoresistance of the EC cells NT2 CisR. (D) NLR-NT2 CisR cells retain low migratory potential in the presence of rhDNase in vitro . (E) Tumor cell chemosensitivity to cisplatin is significantly higher in the direct coculture of healthy donor Nθ in the presence of the rhDNase.
Article Snippet: NTERA-2 (ATCC® CRL1973TM) labeled NT2 cells throughout the manuscript, Tera-2 cells (ATCC® HTB-106TM, kindly provided by Dr. Ludmila Boublikova, Charles University and University Hospital in Motol, Prague, the Czech Republic) and testicular fibroblasts Hs 1.Tes (ATCC® CRL-7002TM) were cultivated in high‐glucose (4.5 g/L) DMEM (Sigma-Aldrich®) supplemented with 10% FBS (GIBCO TM ), 10,000 IU/mL penicillin (Biotika, Slovakia), 5 μg/mL streptomycin and 1x GlutaMAX TM -I Supplement (GIBCO TM ).
Techniques: In Vitro